- Open Access
Chloroquine for COVID-19: rationale, facts, hopes
Critical Care volume 24, Article number: 210 (2020)
The tragedy of the pandemic coronavirus disease 2019 (COVID-19) led to a desperate search for effective treatments. Chloroquine (CQ), an aminoquinoline used for many years for the prophylaxis and therapy of malaria and autoimmune diseases, has been put forward as a treatment option.
The fact that CQ is not patented and has been in clinical use for years is a major advantage. CQ has been shown to have antiviral effects in SARS, MERS, Ebola, and HIV infections, but without data showing clinical effectiveness [1, 2]. Does the current level of evidence suffice for prescribing CQ for COVID-19?
Not every exposure to SARS-CoV-2 correlates with infection, since its infectivity also depends on environmental and host characteristics. Emerging evidence suggests the progression of COVID-19 is characterized by two possibly overlapping phases. During the early phase, host viral load is high, and even in the presence of pneumonia, systemic damage is limited. In the later phase, viral load decreases, but elevated cytokine levels and a hyper-inflammatory response are accompanied by damage to other organs .
Several mechanisms have been proposed to assume that CQ or hydroxychloroquine (HCQ) may be effective against SARS-CoV-2 (Fig. 1) [1, 2]:
Cell models of SARS-CoV-1 infection treated with CQ show interference with the glycosylation of ACE-2 receptors, proposed as the site of SARS-CoV-2 cell binding.
CQ/HCQ increases the pH of acidic cellular organelles, hindering the intermediate stages of endocytosis and virion transport and post-translational modification of newly synthesized viral proteins.
CQ/HCQ can counter the process of virion assembly and viral protein synthesis.
CQ also downregulates cytokine (e.g., TNF-α) production by monocyte-macrophages.
Although these effects suggest CQ/HCQ may affect infectivity and replication of SARS-CoV-2, previous experience with drugs attempting to modulate virus infection and the autoimmune septic response at the cellular level shows that bench and bedside results do not always correlate.
The first description of CQ in SARS-CoV-2 infection was an in vitro study evaluating the effect of five antiviral drugs on infected Vero E6 cells. CQ showed effectivity at clinically acceptable concentrations [EC90 6.90 μM] . The authors provided no information about the CQ formulation used. HCQ sulfate manifested similar effects with a significantly lower EC50 . Another preclinical study confirmed the superiority of HCQ sulfate over CQ phosphate, by showing lower EC50 and higher inhibition rates . Based on pharmacokinetic models, these authors proposed that a loading dose of 400 mg BID HCQ sulfate, followed by 200 mg BID, would maintain effective drug concentration in lung tissue.
One observational study reported data on treatment with HCQ sulfate in patients infected with SARS-CoV-2 in France. The authors compared nasopharyngeal swab viral loads over 6 days in 20 patients treated with HCQ sulfate (200 mg TID for 10 days) and in 16 patients who refused or had contraindication to treatment . The clinical severity of the patients ranged between asymptomatic and pneumonia, but none was critical. On the sixth day, less patients had a detectable viral load in the HCQ group and the effect seemed more evident in the six patients who received azithromycin in addition to HCQ. The small number of participants (n = 36), lack of control for confounders, brief follow-up, and substantial loss to follow-up among those treated (23%, 6/26) limit the validity of these findings. The authors also did not use an intention-to-treat analysis, although they did declare the reasons for patient dropouts. Finally, the indications for combined HCQ-azithromycin treatment were not described. On April 3, the International Society of Antimicrobial Chemotherapy (ISAC) declared that “The ISAC Board believes the article does not meet the Society’s expected standard, especially relating to the lack of better explanations of the inclusion criteria and the triage of patients to ensure patient safety.” highlighting that “the need for fast release of new data should not reduce the quality of scientific scrutiny” .
And what about the safety profile of CQ/HCQ? This too derives from their long-term use in other clinical settings. Common side effects are QT prolongation, hypoglycemia, mental status changes, and retinopathy. Monitoring of heart rate and the QT interval, glucose levels, hepatic and renal function, and clinical screening for mental and visual disturbances are therefore recommended in patients receiving these drugs .
Despite lack of proof, guidelines of several countries propose various formulations of CQ for consideration in the treatment of patients with COVID-19, often referring to locally available formulations. The base form of CQ/HCQ is dissimilar from phosphate or sulfate formulations; 300 mg of CQ base corresponds to 500 mg of CQ phosphate, while 155 mg of HCQ base corresponds to 200 mg of HCQ sulfate. Chinese guidelines proposed CQ phosphate 500 mg BID for 7 days . The Italian Society of Infectious Diseases recommends 500 mg CQ phosphate or 200 mg HCQ sulfate BID for 10 days regardless of severity, but recommends against prophylactic use . The COVID-19 Surviving Sepsis Campaign guidelines made no recommendation on the use of CQ/HCQ in critically ill COVID-19 patients due to insufficient evidence .
A large number of ongoing trials  are an indicator of an idea gone rampant, not an indicator of effectiveness. Only a rigorous randomized controlled trial (RCT) can provide reliable and generalizable data regarding clinical effects of CQ/HCQ in COVID-19 . The WHO recently published a global call to join an adaptive RCT of treatment in patients with COVID-19 . The trial aims to establish the efficacy and safety of antiviral treatments on mortality in this population, and CQ is one of the four treatment arms.
In the frenzy to save patients, the story of CQ may be repeated: description of in vitro activity against SARS-CoV-2 of an “old drug” (as the recent case of the anti-parasitic ivermectin ), drawing huge media attention and incentivizing early publication of small studies in humans and empirical clinical use without quality data collection. Regardless of public pressure, clinicians should adhere to the national authorities’ regulations for prescribing off-label and experimental drugs, including CQ/HCQ.
Availability of data and materials
Twice a day
Coronavirus disease 19
Half-maximal effective concentration
90% effective concentration
Human immunodeficiency virus
Middle East respiratory syndrome
Randomized controlled trial
Severe acute respiratory syndrome
Three times a day
World Health Organization
Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003;3:722–7.
Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020. https://doi.org/10.1016/j.jcrc.2020.03.005.
Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020. https://doi.org/10.1038/s41418-020-0530-3.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–71.
Liu J, Can R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020. https://doi.org/10.1038/s41421-020-0156-0.
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infec Dis. 2020. https://doi.org/10.1093/cid/ciaa237.
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Giordanengo V, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020. https://doi.org/10.1016/j.ijantimicag.2020.105949.
ISAC. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial (Gautret P et al. PMID 32205204). Available from https://www.isac.world/news-and-publications/official-isac-statement Accessed 7 Apr 2020.
FDA. Chloroquine phosphate. 2009. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/083082s050lbl.pdf; Accessed 30 Mar 2020.
Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) (Released by National Health Commission & State Administration of Traditional Chinese Medicine on March 3, 2020). 2020. https://www.chinalawtranslate.com/wp-content/uploads/2020/03/Who-translation.pdf Accessed 30 Mar 2020.
Gruppo collaborativo COVID-19 Lombardia. Vademecum per la cura delle persone con malattia da COVID-19 Edizione 2.0, 13 marzo 2020. 2020. http://www.simit.org/medias/1569-covid19-vademecum-13-03-202.pdf Accessed 30 Mar 2020.
Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020. https://doi.org/10.1007/s00134-020-06022-5.
Kalil AC. Treating COVID-19—off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA. 2020. https://doi.org/10.1001/jama.2020.4742.
WHO. Coronavirus disease (COVID-19) technical guidance: early investigations protocols. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/early-investigations; Accessed 30 Mar 2020.
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020. https://doi.org/10.1016/j.antiviral.2020.104787.
Dr. Cortegiani is an advisory board member of Critical Care.
Ethics approval and consent to participate
Consent for publication
All the authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Cortegiani, A., Ippolito, M., Ingoglia, G. et al. Chloroquine for COVID-19: rationale, facts, hopes. Crit Care 24, 210 (2020). https://doi.org/10.1186/s13054-020-02932-4